Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q - Seite 2
Sabizabulin, a microtubule disruptor, is being developed as a Phase 3 clinical trial for the treatment of hospitalized patients with viral-induced ARDS. The Company does not intend to undertake further development of sabizabulin for the treatment of viral-induced ARDS until we obtain funding from government grants, pharmaceutical company partnerships, or other similar third-party external sources.
The Company also has an FDA-approved commercial product, the FC2 Female Condom (Internal Condom), for the dual protection against unplanned pregnancy and sexually transmitted infections.
Lesen Sie auch
Forward-Looking Statements
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, express or implied
statements related to whether and when the planned phase 2b trial of enobosarm discussed above will commence or produce topline data or patients will progress into the extension study, the planned
design, timing, endpoints, patient population and patient size of such trial and whether such trial will successfully meet any of its endpoints, expectations for the rest of the Company’s
development pipeline, the timing of the Company’s delinquent Form 10-Q filing and other future filings, whether Nasdaq will accept the Company’s plan to regain compliance with Nasdaq listing
standards and the timing of regaining compliance with Nasdaq listing standards, the potential magnitude of the actual expenses to be recorded and the length of time that the Company’s cash is
expected to last. The words "anticipate," "believe," "could," "expect," "intend," "may," "opportunity," "plan," "predict," "potential," "estimate," "should," "will," "would" and similar expressions
are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based upon
current plans and strategies of Veru Inc. (the Company) and reflect the Company's current assessment of the risks and uncertainties related to its business and are made as of the date of this press
release. The Company assumes no obligation to update any forward- looking statements contained in this press release because of new information or future events, developments or circumstances. Such
forward-looking statements are subject to known and unknown risks, uncertainties and assumptions, and if any such risks or uncertainties materialize or if any of the assumptions prove incorrect,
our actual results could differ materially from those expressed or implied by such statements. Factors that may cause actual results to differ materially from those contemplated by such
forward-looking statements include, but are not limited to, the risks detailed in the Company’s periodic reports filed with the SEC, including the Company's Form 10-K for the year ended September
30, 2023.